Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 20,000 shares at $130.58 ($2.7M) on 2018-12-10, disclosed to the SEC on 2018-12-12.
Open-market sale of $2.7M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.58 | 969 | $127K | 4.7% |
| 2 | $132.09 | 2,001 | $264K | 9.8% |
| 3 | $133.00 | 2,104 | $280K | 10.3% |
| 4 | $134.31 | 2,049 | $275K | 10.2% |
| 5 | $135.04 | 2,377 | $321K | 11.8% |
| 6 | $136.48 | 400 |
| $55K |
| 2.0% |
| 7 | $137.39 | 100 | $14K | 0.5% |
| 8 | $134.63 | 647 | $87K | 3.2% |
| 9 | $135.76 | 1,153 | $157K | 5.8% |
| 10 | $136.79 | 3,393 | $464K | 17.1% |
| 11 | $137.63 | 2,407 | $331K | 12.2% |
| 12 | $139.05 | 1,100 | $153K | 5.6% |
| 13 | $140.15 | 1,200 | $168K | 6.2% |
| 14 | $140.61 | 100 | $14K | 0.5% |
| Total | $135.47 avg | 20,000 | $2.7M | 100% |
| Filing → |
| LOXO | SELL | 2018-10-05 | $5.4M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $5.0M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $4.6M | — | Filing → |